Search company, investor...

Predict your next investment

Corporate Venture
boxercap.com

Investments

121

Portfolio Exits

43

About Boxer Capital

Boxer Capital is a vehicle for Tavistock Life Science's investment in a portfolio of public companies and private equity crossover opportunities. Boxer Capital leverages its internal expertise in evaluating pre-clinical and clinical data to generate outsized returns for company founders and employees as well for its investor the Tavistock Group. Boxer Capital has a focus on biotechnology drug development companies across multiple therapeutic indications.

Headquarters Location

P.O. Box 9000

Windermere, Florida, 34786,

United States

Want to inform investors similar to Boxer Capital about your company?

Submit your Analyst Briefing to get in front of investors, customers, and partners on CB Insights’ platform.

Latest Boxer Capital News

Abivax SA raises €130m to advance obefazimod to Phase III

Feb 23, 2023

Abivax SA raises €130m to advance obefazimod to Phase III French Abivax SA has raised €130m capital led by TCGX to accelerate Phase III testing of its ulcerative colitis candidate obefazimod extend its cashflow. Existing investors Invus, Deep Track Capital, Sofinnova Partners, Venrock Healthcare Capital Partners, as well as from new investors Great Point Partners, LLC, Deerfield Management Company, Commodore Capital, Samsara BioCapital, Boxer Capital and others participated in the overtsubscribed reserved capital increase through the issuance of 20,000,000 newly-issued ordinary shares with a nominal value of €0.01 per share, representing 89.6% of its current share capital, at a subscription price of €6.50 per share. Prof. Hartmut J. Ehrlich, M.D., CEO of Abivax said: “Based on our consistent Phase IIa and Phase IIb data, we expect that the Phase III studies will support the short- and long-term efficacy and safety profile of obefazimod.” Alongside the launch and continuation of the clinical programs of obefazimod (ABX464), the company extended its cash runway until the end of the second quarter of 2024. For ulcerative colitis, Abiivax’  pivotal Phase III program started enrollment in October 2022. The program will combine two induction trials and one single maintenance trial, involving a total of 1,200 patients and over 600 clinical study centres, mainly in North America, Europe, Latin America and Asia Pacific. Abivax will invest 80% of the proceeds into the Phase III trial of obefazimod, R&D on the compound’s mechanism of action, nonclinical work, chemical and pharmaceutical development work, regulatory and pharmacovigilance activities for obefazimod. Around 10% will be invested into the remaining clinical activities for obefazimod outside the ulcerative colitis indication such as a Phase IIa maintenance trial in rheumatoid arthritis and various current and future Phase I trials necessary to prepare potential submissions for marketing authorisations for obefazimod. Abivax said that it will require additional financing of €101m to complete its Phase III clinical program for obefazimod in UC.

Boxer Capital Investments

121 Investments

Boxer Capital has made 121 investments. Their latest investment was in Abivax as part of their PIPE - III on February 2, 2023.

CBI Logo

Boxer Capital Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

2/22/2023

PIPE - III

Abivax

$137.85M

Yes

1

11/2/2022

Series A

Lusaris Therapeutics

$60M

Yes

12

11/2/2022

Series A - II

Alterome Therapeutics

$35M

No

5

9/7/2022

PIPE

Subscribe to see more

$99M

Subscribe to see more

10

3/31/2022

Series B

Subscribe to see more

$99M

Subscribe to see more

10

Date

2/22/2023

11/2/2022

11/2/2022

9/7/2022

3/31/2022

Round

PIPE - III

Series A

Series A - II

PIPE

Series B

Company

Abivax

Lusaris Therapeutics

Alterome Therapeutics

Subscribe to see more

Subscribe to see more

Amount

$137.85M

$60M

$35M

$99M

$99M

New?

Yes

Yes

No

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

1

12

5

10

10

Boxer Capital Portfolio Exits

43 Portfolio Exits

Boxer Capital has 43 portfolio exits. Their latest portfolio exit was Enliven Therapeutics on February 23, 2023.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

2/23/2023

Reverse Merger

$99M

4

9/15/2022

IPO

$99M

Public

18

8/10/2022

Acq - Pending

$99M

2

9/15/2021

IPO

Subscribe to see more

$99M

Subscribe to see more

10

8/5/2021

Acquired

Subscribe to see more

$99M

Subscribe to see more

10

Date

2/23/2023

9/15/2022

8/10/2022

9/15/2021

8/5/2021

Exit

Reverse Merger

IPO

Acq - Pending

IPO

Acquired

Companies

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

$99M

$99M

Acquirer

Public

Subscribe to see more

Subscribe to see more

Sources

4

18

2

10

10

Boxer Capital Team

7 Team Members

Boxer Capital has 7 team members, including current Founder, Chief Executive Officer, Aaron Davis.

Name

Work History

Title

Status

Aaron Davis

Founder, Chief Executive Officer

Current

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Name

Aaron Davis

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Work History

Title

Founder, Chief Executive Officer

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Current

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.